Cognitive Drug Research Signs Development Agreement With Pharma Services Network
Cognitive Drug Research (CDR) has formed an alliance with Pharma Services Network to further their business in North America.
Goring-on-Thames /Charlotte: Cognitive Drug Research (CDR), whose testing system has long been recognized as the Gold Standard in cognitive testing, has formed an alliance with Pharma Services Network to further their business in North America. "This agreement with Pharma Services Network allows us to further extend our reach in the cognitive testing market in the United States," said Professor Keith Wesnes, Chief Executive of CDR. "Of course, the USA represents the largest market in the world for our services, so it is natural that we should expand our capabilities there."
Cognitive Drug Research is a specialty clinical service provider with over 20 years experience in helping USA drug manufacturers demonstrate the tangible real life implications of the effects of their medications. Cognitive Drug Research has delivered cognitive testing at over 1000 study sites and has completed over 500 clinical trials. The CDR computerized assessment battery has become the most widely used cognitive testing system in the world and the resulting databases are the largest and most complete of their kind.
"CDR is clearly the leader in this field," said Stephen Worrell, Vice President of Pharma Services Network. "And the benefits they bring to Sponsors range from early go/no go decisions to supporting marketing campaigns with cognitive endpoints. Data from CDR's studies have been used as primary endpoints in successful FDA approvals and are 21 CFR part 11 compliant. The fact that the system is simple, fits seamlessly into any trial design, and at any stage, makes it a compelling element of a company's risk management strategy."
A staff of over 50 in-house skilled personnel including expert scientists, psychologists and statisticians provide full support from protocol design and consultation to analysis. Their emphasis on service, technology and quality resulted in receiving The Queens Award for Enterprise in both the International Trade category (2002) and in the Innovation category (2003).
Pharma Services Network is a business development company working on behalf of international research organizations, helping them build strong business relationships with US pharmaceutical and biotech companies.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Integrated Multi-Omic Data: Powering Precision Medicine
March 10th 2025Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help attain a more complete picture of how an individual’s complex biology impacts their health profile.
